DRTS Stock Gets A Pre-Market Boost – Retail Shrug Off Wider Q1 Loss Ahead Of Key Pancreatic Cancer Data Reveal This Week

• The 58-patient studies were conducted at hospitals in Canada and Israel.
• Alpha Tau posted a net loss of $0.26 per share for the first quarter, compared to Wall Street’s estimates of a loss of $0.12 per share, according to Fiscal.ai data.
• Alpha Tau said it expects to complete patient enrollment in its IMPACT pancreatic cancer pilot study in the U.S. during the third quarter.

Alpha Tau Medical (DRTS) was back on investors’ radar on Tuesday ahead of a closely watched data release later this week, when the company is expected to unveil pooled results from three studies evaluating the safety and efficacy of its Alpha DaRT therapy in patients with pancreatic cancer.

DRTS shares were up 3% in pre-market trading.

DRTS To Participate At ASCO 2026

Last month, the biotech firm said an abstract, titled “Combined Safety and Efficacy Results from Three Clinical Studies Evaluating Alpha Radiotherapy for Advanced Pancreatic Cancer,” was accepted for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026, scheduled for May 29 to June 2. The abstract is set to be published on May 21.

The studies were conducted at hospitals in Canada and Israel and included 58 patients. Alpha DaRT is a therapy that places radioactive sources directly inside tumors to locally destroy cancer cells.

DRTS Issues Key Timelines For Cancer Study Milestones

On Monday, Alpha Tau said it expects to complete patient enrollment in its IMPACT pancreatic cancer pilot study in the U.S. during the third quarter (Q3), with initial data expected in late 2026 or early 2027. It also plans to finish recruitment for the REGAIN recurrent glioblastoma trial in the second half of 2026, with additional results expected around year-end 2026.

Meanwhile, top-line data from the ReSTART pivotal U.S. multi-center trial in recurrent cutaneous squamous cell carcinoma is expected around the end of 2026.

Alpha Tau posted a net loss of $0.26 per share for the first quarter (Q1), compared to Wall Street’s estimates of a loss of $0.12 per share, according to Fiscal.ai data. Research and development expenses rose to $11 million from $7.2 million a year earlier, primarily driven by higher clinical trial activity.

What Retail Thinks About DRTS

Retail sentiment for DRTS on Stocktwits has remained in the ‘neutral’ territory over the past 24 hours

One bullish user said a larger R&D burn is expected as the company scales its pipeline.

Another user highlighted the firm’s strong cash position ahead of the ASCO event.

Alpha Tau said its cash, cash equivalents, short-term deposits, and restricted deposits balance stood at $80.2 million at the end of the quarter, offering a strong runway for clinical and commercial operations.

The stock has nearly doubled so far in 2026.

Read also: Billionaire Mark Cuban Says Crypto's Biggest Players Now Want More Regulation, Not Less

For updates and corrections, email newsroom[at]stocktwits[dot]com.